Abstract
Two square planar Rh(I) organometallic complexes namely [Rh(L1)(cod)]Cl (cod = cycloocta-1,5-diene, L1=2,2′-pyridylquinoxaline (1-Cl), [Rh(L1)(cod)](NO3) (1-NO3) and a series of novel octahedral rhodium(III) complexes of the general formulae mer-[Rh(L1)Cl3(MeOH)] (2) and cis-[Rh(L2)2Cl2]Cl (L2=4 carboxy 2 (2′ pyridyl)quinoline (3), L3=2,2′ bipyridine 4,4′ dicarboxylic acid (4) were synthesized and characterized spectroscopically. All the synthesized compounds including the previously prepared cis-[Rh(L1)2Cl2]Cl complex (5) were biologically evaluated as potential inhibitors of the Platelet Activation Factor (PAF) and thrombin induced aggregation. In particular compounds 1-Cl and 1-NO3 were found to be strong inhibitors of PAF with IC50 values in the range of 16nM and 15nM rendering them good candidates for further investigation. Their potency is comparable to that of the widely used PAF receptor antagonists WEB2170, BN52021, and Rupatadine (IC50 of 20, 30 and 260nM respectively). Molecular docking calculations suggest that 1-Cl, 1-NO3 and 2 can be accommodated within the ligand-binding site of PAF receptor and block the activity of PAF. On the other hand, the octahedral rhodium(III) complexes 3–5 that cannot fit the ligand-binding domain, could potentially exhibit their activity at the extracellular domain of the receptor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
